Latest Clinical News

Keytruda Trail Results Suggest Change in Management of Squamous Non-Small Cell Lung Cancer (06-22-2018)

An interim analysis of the phase III KEYNOTE-407 trial evaluated combined chemotherapy and immunotherapy showed a more than four-month longer median overall survival for metastatic squamous non–small-cell lung cancer (NSCLC) patients who received keytruda... Continue Reading

U.S. FDA Agrees to Review Talazoparib for Advanced and Triple Negative Breast Cancer for Treatment of Patients with an Inherited BRCA Mutation (06-21-2018)

The U.S. Food and Drug Administration accepted for filing and granted Priority Review designation for Pfizer’s New Drug Application for talazoparib. The submission is based on results from the EMBRACA trial, which compared talazoparib to chemotherapy... Continue Reading

mFOLFIRINOX Found Superior to Gemzar for Treatment Surgically Resected Pancreatic Cancer (06-19-2018)

The results of a recently presented clinical study at the American Society of Clinical Oncology meetings last week suggest that more aggressive chemotherapy treatment improves outcomes compared to single agent Gemzar (gemcitabine) chemotherapy which has... Continue Reading

Newly Diagnosed with Ovarian Cancer? 10 Must Read Tips to be an Empowered Patient (06-18-2018)

For many years ovarian cancer has been referred to as “the silent killer” due to its vague, ignored, or misdiagnosed symp­toms. Because of this and the lack of ear­ly-detection tools, ovarian cancer often goes undiagnosed until it has reached the... Continue Reading

FDA Approves Merck’s Keytruda® for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (06-18-2018)

The U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1.  Keytruda is the... Continue Reading

University of Colorado Study Suggests new Combination Treatment for Head and Neck Cancer (06-14-2018)

The five-year survival rate for locally-advanced head and neck cancer is only 46 percent, even with treatments including surgery, radiation, chemotherapy and/or genetically targeted treatments such as cetuximab. Often, the problem is that while treatments... Continue Reading

Vicinium Represents New Treatment Option for Non- Muscle Invasive Badder Cancer (06-6-2018)

Today three-month data from the ongoing Phase 3 VISTA Trial of Vicinium for the treatment of patients with high-grade non-muscle invasive bladder cancer (NMIBC) who have been previously treated with bacillus Calmette-Guérin (BCG) were released. Overall... Continue Reading

Xalkori Receives FDA Breakthrough Therapy Designation for Treatment of Lung Cancer with MET Alterations (06-5-2018)

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Xalkori (crizotinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with MET exon 14 alterations with disease progression on or... Continue Reading

Loxo-292 Promising for Lung and Other “RET Fusion” Cancers (06-4-2018)

On Saturday, Loxo Oncology in a presentation at the American Society of Clinical Oncology annual meeting in Chicago unveiled clinical trial data for LOXO-292, a novel precision cancer medicine targeting tumors containing a mutated protein known as RET. About... Continue Reading

FDA Grants Approval of Calquence for the Treatment of Mantle Cell Lymphoma (05-31-2018)

The US Food and Drug Administration (FDA) has granted approval to Calquence (acalabrutinib) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Calquence is a highly-selective, potent Bruton tyrosine... Continue Reading

Interim Survival Data from Phase 3 Trial of DCVax®-L for Glioblastoma Reported (05-30-2018)

Northwest Biotherapeutics, developer of DCVax® personalized immune therapies for solid tumor cancers, announced today the publication of interim blinded survival data from its Phase 3 clinical trial of DCVax®-L for newly diagnosed Glioblastoma brain... Continue Reading

Interim Results from Clinical Trial of Immunotherapy for Glioblastoma Show Significant Clinical Benefit (05-29-2018)

The research team behind an emerging immunotherapy for cancer will present interim findings from an ongoing clinical study in patients with brain cancer at a major research meeting next month. Collaborators from organizations including Roswell Park Comprehensive... Continue Reading

Next Page »